Search Results for "Lupron"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lupron. Results 1 to 10 of 17 total matches.
See also: leuprolide acetate
Goserelin - Another LH-RH Analog for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990 (Issue 830)
-releasing hormone (LH-RH) analog similar
to leuprolide (Lupron; Lupron Depot) (Medical Letter, 27:71, 1985 ...
The US Food and Drug Administration recently approved the marketing of goserelin acetate (Zoladex - ICI Pharma), an implant for palliative treatment of advanced prostate cancer. Goserelin acetate is a synthetic decapeptide luteinizing hormone-releasing hormone (LH-RH) analog similar to leuprolide (Lupron; Lupron Depot) (Medical Letter, 27:71, 1985).
Flutamide For Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989 (Issue 797)
) such as leuprolide
(Lupron - Medical Letter, 27:71, 1985).
MECHANISM OF ACTION — Flutamide inhibits the uptake ...
Flutamide (Eulexin - Schering), an oral antiandrogen, is now available in the USA for treatment of metastatic prostate cancer. Flutamide is recommended by the manufacturer only for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron - Medical Letter, 27:71, 1985).
Bicalutamide for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996 (Issue 977)
with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot ...
Bicalutamide (Casodex - Zeneca), an oral nonsteroidal antiandrogen similar to flutamide (Eulexin - Medical Letter, 31:72, 1989), is now available in the USA for treat-ment of advanced prostate cancer. The drug is recommended by the manufacturer for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot) or goserelin (Zoladex -Medical Letter, 32:102, 1990).
Triptorelin Pamoate (Trelstar)
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002 (Issue 1132)
(Sanofi-Synthelabo) 7.5 mg/month SC 643.75
3
Lupron Depot (TAP) 7.5 mg/month IM 643.75
or 22.5 mg/12 ...
Two controlled-release formulations of triptorelin (trip toe rel' in) pamoate, an agonist analog of human luteinizing hormone-releasing hormone (LHRH), are now available in the US for parenteral treatment of advanced prostate cancer. Trelstar Depot is given every 4 weeks and Trelstar LA every 12 weeks. Triptorelin has been available in some countries since 1986.
Nafarelin For Endometriosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 1990 (Issue 825)
available products with this mechanism of action include, in addition to nafarelin, leuprolide (Lupron ...
Nafarelin acetate (Synarel - Syntex), a synthetic analog of gonadotropin-releasing hormone (GnRH), was recently approved by the US Food and Drug Administration for treatment of endometriosis. The drug is available only in a nasal spray formulation.
Triptorelin (Triptodur) for Central Precocious Puberty
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
)
Leuprolide acetate – 7.5, 11.25, 15 mg syringes (once/month kit) 7.5-15 mg IM once/month2 29,3343
Lupron ...
The FDA has approved an extended-release
intramuscular suspension formulation of the
gonadotropin-releasing hormone (GnRH) agonist
triptorelin (Triptodur – Arbor/Debiopharm) for twice-yearly
treatment of central precocious puberty (CPP)
in children ≥2 years old. Triptorelin has been available
in the US for years as Trelstar for palliative treatment
of advanced prostate cancer. Before the approval
of Triptodur, Trelstar was used off-label for treatment of CPP.
Leuprolide Acetate (Fensolvi) for Central Precocious Puberty (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
Histrelin acetate – 50 mg SC implant q12 mos
Supprelin LA (Endo) $43,069
Leuprolide acetate2 –
Lupron ...
Fensolvi (Tolmar), a long-acting subcutaneous formulation
of the gonadotropin-releasing hormone (GnRH)
agonist leuprolide acetate, has been approved by the
FDA for treatment of central precocious puberty (CPP)
in children ≥2 years old. It is the first formulation of
the drug to be approved for SC administration once
every 6 months. IM formulations of leuprolide acetate,
which are given once monthly or every 3 months, and
the GnRH agonists histrelin acetate (Supprelin LA) and
triptorelin (Triptodur) have been available for years for
treatment of CPP.
Abarelix (Plenaxis) for Advanced Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004 (Issue 1178)
7.5 mg/month SC 611.56
Lupron Depot (TAP)
4
7.5 mg/month IM 685.21
Viadur (Bayer)
5
65 mg/12 mos ...
Abarelix (Plenaxis - Praecis Pharmaceuticals), an injectable gonadotropin-releasing hormone (GnRH) antagonist, has been approved by the FDA for treatment of advanced symptomatic prostate cancer in patients who should not take luteinizing hormone-releasing hormone (LHRH) agonists and who refuse treatment with surgical castration.
Preservation of Ovarian Function During Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
in the US: leuprolide acetate (Lupron, and others), nafarelin acetate
(Synarel), triptorelin pamoate (Trelstar ...
Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility
counseling followed by appropriate action may prevent some of these undesirable consequences.
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
adequate relief, GnRH agonists such
as subcutaneously injected leuprolide (Lupron,
and others ...
The FDA has approved elagolix (Orilissa – AbbVie),
an oral gonadotropin-releasing hormone (GnRH)
antagonist, for management of moderate to severe
pain associated with endometriosis.